Outlook Wealth Advisors LLC Invests $433,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Outlook Wealth Advisors LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, HoldingsChannel reports. The firm bought 1,302 shares of the company’s stock, valued at approximately $433,000.

Several other hedge funds also recently made changes to their positions in MEDP. Stone House Investment Management LLC purchased a new position in Medpace during the third quarter valued at $33,000. Ashton Thomas Securities LLC bought a new position in shares of Medpace in the 3rd quarter worth about $37,000. Capital Performance Advisors LLP purchased a new position in Medpace during the 3rd quarter valued at about $46,000. True Wealth Design LLC boosted its stake in Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after acquiring an additional 168 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in Medpace by 191.4% during the third quarter. UMB Bank n.a. now owns 271 shares of the company’s stock worth $90,000 after acquiring an additional 178 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Price Performance

NASDAQ MEDP opened at $335.23 on Thursday. The stock has a market capitalization of $10.42 billion, a PE ratio of 29.35, a P/E/G ratio of 1.80 and a beta of 1.36. The business has a 50 day simple moving average of $341.36 and a two-hundred day simple moving average of $358.26. Medpace Holdings, Inc. has a 1-year low of $277.72 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million for the quarter, compared to analysts’ expectations of $540.99 million. During the same period in the prior year, the company earned $2.22 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. On average, analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.